- Trials with a EudraCT protocol (51)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (22)
51 result(s) found for: Median nerve.
Displaying page 3 of 3.
EudraCT Number: 2019-001458-24 | Sponsor Protocol Number: ALN-TTR02-011 | Start Date*: 2019-09-19 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (... | |||||||||||||
Medical condition: Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) BG (Completed) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003222-76 | Sponsor Protocol Number: ZX008-2103 | Start Date*: 2022-08-19 | |||||||||||
Sponsor Name:Zogenix International Limited | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EXAMINE THE EFFICACY AND SAFETY OF ZX008 IN SUBJECTS WITH CDKL5 DEFICIENCY DISORDER FOLLOWED BY AN OPEN-LABE... | |||||||||||||
Medical condition: CDKL5 DEFICIENCY DISORDER | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Trial now transitioned) DE (Trial now transitioned) FR (Not Authorised) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006168-31 | Sponsor Protocol Number: E2007-G000-305 | Start Date*: 2008-08-28 |
Sponsor Name:Eisai Ltd | ||
Full Title: A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial S... | ||
Medical condition: Epilepsy: refractory partial seizures with or without secondary generalisation | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) BE (Completed) NL (Completed) DE (Completed) FR (Completed) SE (Completed) GB (Completed) DK (Completed) FI (Completed) IT (Completed) GR (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002167-16 | Sponsor Protocol Number: E2007-G000-311 | Start Date*: 2017-01-30 | ||||||||||||||||
Sponsor Name:Eisai Limited | ||||||||||||||||||
Full Title: An Open-Label, Multicenter Study with an Extension Phase to Evaluate the Safety, Tolerability, and Exposure-Efficacy Relationship of Perampanel Oral Suspension when Administered as an Adjunctive Th... | ||||||||||||||||||
Medical condition: Epilepsy : 1) Partial-Onset Seizures (POS) 2) Primary Generalized Tonic-Clonic Seizures (PGTC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) LV (Completed) ES (Completed) PL (Completed) BE (Completed) IT (Completed) Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-006169-33 | Sponsor Protocol Number: E2007-G000-306 | Start Date*: 2008-07-17 |
Sponsor Name:Eisai Ltd | ||
Full Title: Estudio doble ciego, controlado con placebo, con aumento gradual de dosis, en grupos paralelos para evaluar la eficacia y la seguridad de E2007 (perampanel) administrado como terapia adyuvante en p... | ||
Medical condition: Epilepsia: crisis parciales refractarias con o sin crisis secundarias generalizadas Epilepsy - refractory partial seizures with or without secondary generalisation | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) CZ (Completed) PT (Completed) HU (Completed) EE (Completed) LT (Completed) PL (Completed) LV (Completed) IT (Completed) BG (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003357-17 | Sponsor Protocol Number: Ketamin_SST01 | Start Date*: 2013-11-01 | ||||||||||||||||
Sponsor Name:Prof. Asbjørn Mohr Drewes | ||||||||||||||||||
Full Title: RESET Trial A randomized, double-blinded, single-centre, parallel-group, placebo-controlled, prospective trial of S-ketamine for pain treatment in chronic pancreatitis (RESET trial) | ||||||||||||||||||
Medical condition: Chronic Pancreatitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-002008-33 | Sponsor Protocol Number: A6181196 | Start Date*: 2012-02-21 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR | |||||||||||||
Medical condition: Pediatric Gastro Intestinal Stromal Tumor (GIST) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Completed) Outside EU/EEA CZ (Completed) PT (Completed) IT (Completed) GB (Completed) PL (Completed) AT (Completed) DE (Completed) FR (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005443-14 | Sponsor Protocol Number: NGAM-08 | Start Date*: 2017-04-28 | |||||||||||
Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H. | |||||||||||||
Full Title: Prospective, double-blind, randomized, multicenter phase III study evaluating efficacy and safety of three different dosages of NewGam in patients with chronic inflammatory demyelinating poly(radic... | |||||||||||||
Medical condition: Chronic Inflammatory Demyelinating Poly(radiculo)-neuropathy (CIDP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Prematurely Ended) SE (Prematurely Ended) HU (Completed) CZ (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001758-14 | Sponsor Protocol Number: 201677 | Start Date*: 2015-12-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis | |||||||||||||
Medical condition: Giant Cell Arteritis (GCA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005175-27 | Sponsor Protocol Number: IB2017-01 | Start Date*: 2018-03-14 | ||||||||||||||||||||||||||
Sponsor Name:Institut Bergonié | ||||||||||||||||||||||||||||
Full Title: A phase I/II study of Regorafenib plus Avelumab in digestive tumors | ||||||||||||||||||||||||||||
Medical condition: Adult patients with advanced or metastatic digestive solid tumors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000868-42 | Sponsor Protocol Number: B3461045 | Start Date*: 2016-09-26 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN SUBJECTS DIAGNOSED WITH TRANSTHYR... | |||||||||||||
Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) BE (Completed) CZ (Completed) DE (Completed) SE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
